The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cyclin-dependent kinase 4/6 inhibition for the treatment of mature teratoma germ cell tumor: Long-term follow-up of a phase II study.
 
Vivek Narayan
No Relationships to Disclose
 
Wei-Ting Hwang
No Relationships to Disclose
 
Priti Lal
No Relationships to Disclose
 
Mark Alan Rosen
No Relationships to Disclose
 
Maryann Gallagher
No Relationships to Disclose
 
Peter J. O'Dwyer
Stock and Other Ownership Interests - TetraLogic Pharmaceuticals
Consulting or Advisory Role - Five Prime Therapeutics; Genentech
Research Funding - BBI Healthcare; Bristol-Myers Squibb; Celgene; Genentech; GlaxoSmithKline; Mirati Therapeutics; Novartis; Pfizer
Expert Testimony - Lilly
 
David J. Vaughn
Consulting or Advisory Role - Astellas Pharma; Janssen